Letters

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
• 
Eradication of Hepatitis C Virus after Interferon-a Therapy
To the Editor: I agree with Romeo and colleagues (1) that testing liver biopsy specimens for hepatitis C virus (HCV) RNA is useful in monitoring therapy for HCV infection, but their conclusion is incorrect. They claim that a polymerase chain reaction (PCR) assay that is negative for HCV RNA in a liver biopsy specimen indicates eradication of the virus. As the authors indicated, the sensitivity of their PCR assay is 5 X 10 4 HCV particles/mL of serum, which is the limit of sensitivity of the assay because of the inefficiency of the reverse transcriptase step in the method. Thus, approximately 10 4 particles/mL may still be present with a negative assay result. At present, no method can exclude residual HCV infection. Until a method for detecting a single molecule of HCV RNA is developed, the end point for therapy should be the absence of HCV RNA in the blood by PCR assay and the absence of HCV RNA in the liver by PCR or preferably by in situ hybridization. The patient must then be carefully monitored for relapse by assaying serum samples for HCV RNA. Although eradication of the virus cannot be established, continued absence of relapse empirically indicates elimination of active infection, although residual HCV infection may be present. To the Editor: Hepatitis C virus is the most common cause of chronic liver disease in patients receiving hemodialysis, and renal transplantation is contraindicated in patients with chronic active hepatitis and cirrhosis because of the risk for progression of their liver disease.
Vincent Agnello, MD
Interferon is the most commonly used treatment for HCVrelated chronic hepatitis in patients without uremia. As reported by Romeo and colleagues (1) interferon therapy may lead to complete eradication of virus in some long-term responders.
However, these investigators mentioned that patients on hemodialysis cannot receive interferon therapy.
Data about the effectiveness of interferon therapy in patients receiving hemodialysis are limited, but short-term results are promising (2) (3) (4) (5) . Toxic effects of interferon were mild and selflimited when the dosage of interferon was 3 million units three times a week (2, 3), although Vogel and colleagues (4) reported serious side effects when interferon was used at 5 million units three times a week. Thus, interferon therapy may not be contraindicated in these patients.
In fact, we believe that interferon therapy with close follow-up for side effects such as leukopenia may be useful in patients with HCV-related chronic liver disease who receive hemodialysis. In response: We agree with Dr. Agnello that a few copies of HCV RNA may exist after interferon treatment even if PCR results are negative. Nevertheless, the inability to detect HCV RNA in the serum, liver, and peripheral blood mononuclear cells is a strong argument for eradication, given the long-term follow-up of these patients who continue to have normal liver function and normal liver histologic results. A longer follow-up of these patients should confirm our hypothesis of the absence of substantial HCV infection.
In regard to the letter by Dr. Akpolat and colleagues, we never stated that hemodialysis was a contraindication to interferon-a therapy. On the contrary, our center has initiated such studies (1) . The potential interest of this approach is reinforced by the low viremia that is observed in patients who receive hemodialysis (2) and is an independent positive predictive factor of the response to interferon (3) . In addition, the need for treating patients on hemodialysis is underlined by the frequent histopathologic deterioration observed in 70% of persons receiving kidney transplants who have HCV infection (4) .
Interferon-a therapy for patients who have hemodialysis does, however, imply that patients should be carefully monitored for potential side effects (1) . In addition, biological variables (such as alanine aminotransferase levels) and virologic variables (such as serum HCV-RNA) can be difficult to evaluate in these patients because of the presence of renal disease, concomitant treatment with other drugs, and immunodepression. The potential pitfalls clearly indicate the need for careful evaluation and monitoring in these patients. 
Running and the Development of Disability with Age
To the Editor: The risks and benefits of regular vigorous exercise are revisited in the observational report by Fries and colleagues (1). In their ongoing comparison between the members of a self-selected running club and a Stanford University lipid study group, the authors report that runners have less disability and lower mortality as they age than do staff and faculty members who do not run. However, there is a hitch.
The data presented clearly show that the university control group increased its total burden of vigorous exertion from 77.3 minutes per week in 1984 to 124.1 minutes per week 8 years later (an increase of 61%). By contrast, the total weekly time for gifted athletes in the running club decreased from 301.4 minutes in 1984 to 278.8 minutes in 1992 (a decrease of vigorous exertion of 7.5%). Rather than suggesting that running is good for aging men and women, these data may indicate that increased indulgence in strenuous exercise late in life may be rewarded with increased injury. Until prospective, controlled trials of exercise are done, we may not know whether vigorous exercise incapacitates, heals, or merely entertains (2, 3).
Donald Venes, MD Portland, OR 97207-8277
In response: We thank Dr. Venes for his comments. Prospective longitudinal studies are required to address questions of long-term benefits or costs of vigorous exercise programs, given that a randomized clinical trial is neither ethical or practical.
(Imagine randomly assigning a large sample to either run 1000 miles a year or to watch television for a decade!) We reported 8-year results of our ongoing study (1) . Please note two arithmetic errors in Dr. Venes's letter. The baseline level of vigorous exertion in the control group was 87.3 minutes per week rather than 77.3. The percentage increase is therefore 42% rather than 61%.
Disability developed in exercisers at only one fourth the rate in nonexercisers, whether we compared our original groups, all exercisers in both groups with nonexercisers, or exercisers and nonexercisers in the community control group. Seven exercisers and 30 controls died.
We recently presented our data after 9 years of study (2) and found that the disability differences between the groups contin ued. Musculoskeletal pain in exercisers had decreased by one fourth. Medical care costs were also one fourth lower in this group. To date, no total joint replacements have been done in the group that exercised initially. As we reported, exercisers sustain many fractures and other short-term injuries, but these do
Triglyceride Levels in Sons of Patients with Coronary Artery Disease
To the Editor: We thank Dr. Grundy (1) for his supportive and useful discussion of our report (2) , in which he considers various explanations for the prolonged postprandial hypertriglyceridemic response in the sons of patients with coronary artery disease. Dr. Grundy suggests that we examine the possible bimodality of responses in the offspring of patients, a bimodality that would theoretically emerge if group differences could be attributed to a heterozygous monogenic defect of triglyceride metabolism in patients. Given this monogenic hypothesis, a subgroup of patients having the gene would transmit it to 50% of their offspring. Consequently, a subgroup of sons would have marked postprandial responses, and Dr. Grundy suggests that these responses may explain the effect that we found.
A classic debate between Piatt and Pickering (reviewed in reference 3) on the mode of transmission of primary hypertension on the basis of the shapes of blood pressure distribution curves has shown that bimodality, as distinct from left-skewing, in such curves is not easily proved. Further, a familially acquired abnormality in only a subgroup of families could theoretically lead to a similar bimodality. This and the relatively small sample size of our study initially led us not to engage in such an analysis. An alternative approach in unravelling putative modes of inheritance is segregation analysis, but such an analysis would not be overly informative in this case because of the limited number of siblings in our study. Nevertheless, we have attempted to address Dr. Grundy's suggestion. Figure 1 shows the frequency distribution of areas under the curve of the triglyceride response for sons of patients 6 to 12 hours after lipid loading. Although not a 
of borderline significance (difference, 0.78 mmol X h/L; 95% CI, -0.015 to 1.574). Thus, it seems that offspring group differences cannot be fully explained by a subgroup of sons of patients with markedly high postprandial responses. Although this analysis must be evaluated with some caution, the monogenic mechanism as the sole explanation for prolonged postprandial hypertriglyceridemia does not appear to be supported by our data. 
Pituitary Adenomas
To the Editor: The article by Kupersmith and colleagues (1) does not mention the findings from magnetic resonance imaging and computed tomography scans in their patients with macroadenoma of the pituitary gland and visual field defects. A hemorrhagic pituitary adenoma during pregnancy may cause an acute increase in the size of the macroadenoma and may cause visual field defects. On the basis of magnetic resonance imaging scans, such pituitary "apoplexy" has been classified as classical, subacute, and asymptomatic (2) . Further, the density of the pituitary adenoma may give an idea of the acuteness of the apoplexy and help distinguish a neoplastic process from a non-neoplastic process (2, 3).
Why did none of the 6 of 8 patients with pituitary macroadenoma who had documented visual field defects have surgical intervention during their pregnancy? Trans-sphenoidal surgical resection of pituitary adenomas during pregnancy is a safe procedure and is the treatment of choice in patients with visual field involvement (4, 5). To the Editor: Kupersmith and colleagues (1) reported that enlargement of pituitary adenomas with baseline heights of 1.2 cm or more in six patients during pregnancy resulted in visual field defects. Such enlargement is relatively common in women with prolactin-secreting macroadenomas (2); however, this is the first report (that I am aware of) of enlargement of a growth hormone-secreting tumor in a patient with acromegaly or a "clinically nonfunctioning" tumor. These tumors did not secrete prolactin. These aspects deserve emphasis because they will influence clinicians with respect to prepregnancy counseling and in follow-up during pregnancy.
Mumtaz A. Siddiqui, MD
Readers should not think that 75% of women with pituitary adenomas 1.2 cm or more in height will develop visual field defects if they become pregnant. Considerable ascertainment bias exists in this study because all patients evaluated were initially seen by an ophthalmologist. In response: Dr. Siddiqui raises two important issues. First, if a patient has an apoplectic event with a pituitary adenoma, he or she might require emergent trans-sphenoidal surgery; such patients, even if they have prolactin-secreting tumors, may not be responsive to bromocriptine. However, none of our patients who had chiasmal compression during pregnancy had manifestations of hemorrhage on either magnetic resonance imaging or computed tomography scans. As is well known, microscopic examination of removed adenomas may show hemorrhage when neuroimaging has not. The second point concerns the question of why patients did not have surgical intervention during pregnancy. As shown by the reported outcomes in our patients with visual loss, emergent surgery is not always necessary. In the one patient with progressive visual loss, surgery was clearly indicated. In other patients with minor field loss, surgery can be withheld until the pregnancy is completed. In patients with prolactinomas, reinstitution of bromocriptine is effective. Because this was not a treatment trial, our data do not dictate that all patients be treated in this manner. This approach, however, has worked for our patients.
Dr. Molitch had an important observation about the low frequency of the growth of nonsecretory or growth hormone-secreting tumors. He wondered whether these tumors could enlarge to a size that would cause visual loss during pregnancy. However, 6 of 8 patients developed visual loss during pregnancy; their tumors were 1.2 cm or more in height. We studied such a small group of patients with macroadenomas during pregnancy because we typically advise some sort of therapy (surgery, radiotherapy, or dopamine-agonist treatment) before pregnancy in patients with pituitary adenomas. We believe it would be too risky to study a large group of patients with macroadenomas to determine the exact incidence of visual loss.
It is irrelevant whether the patients were originally evaluated by a neuro-ophthalmologist with an interest in pituitary tumors or by an endocrinologist. We agree that some adenomas will inferiorly grow to a substantial size without ever causing a visual disturbance. However, because the principal neurologic risk with a pituitary tumor is loss of vision, any patient with a macroadenoma should have visual field examinations at baseline and routine follow-up. It is not sufficient to follow these patients with manual confrontation techniques. 
These letters raise several important points about clinical observation, interpretation of associations, and causation in individual cases. First, new observations by astute clinicians alert the medical community to associations between exposure and disease onset. Second, these associations must be examined to determine whether the exposure precedes the outcome more often than would be expected because of chance; that is, observation of the case-exposure relation without control data is by necessity inconclusive. Third, even after an association has been established and is believed to be causal, causation cannot be certain in any specific case when the exposure of interest is not a "necessary cause" (3) for disease onset.
Murray A. Mittleman, MD, DrPH
Institute for Prevention of Cardiovascular Disease New England Deaconess Hospital Boston, MA 02215
In response: We appreciate Dr. Mittleman's comments and agree with his summary of the limitations of interpreting causation from a single clinical observation.
In addition to our patient (1), several other patients whose cardiac events were temporally related to smoking while wearing a nicotine patch have been described (2) . The combination of smoking and transdermal nicotine can produce high nicotine levels (3, 4) . Because nicotine produces vasoconstriction, catecholamine release, and platelet aggregation, it may also trigger plaque rupture, leading to the formation of an occlusive thrombus and resulting in myocardial infarction. Although our observation and physiologic plausibility do not establish that smoking while wearing a nicotine patch can trigger cardiac events, we believe that patients with established coronary artery disease should avoid nicotine from any source. Further, all users of nicotine patches should be warned of the additional potential risks associated with smoking.
James G. Warner Jr., MD, EdD William C. Little, MD
The Bowman Gray School of Medicine Winston-Salem, NC 27157
Study of Internal Medicine Manpower: XX
To the Editor: Lyttle and Levy (1) prominently highlight the inroads made by international medical graduates (IMGs) into the subspecialties of internal medicine and project them as an indirect cause of a future shortage of primary care physicians. The 110% cap on residencies may not guarantee a solution but will definitely restrict freedom of choice for all residents. We must seek a solution to the maldistribution of physicians that leads to a significant primary care physician shortage (2) and must not restrict IMG residents who deliver health care to the underserved in many inner-city areas shunned by U.S. graduates. The tendency to specialize may stem in part from the lack of opportunities in their home countries, a factor that prompts IMGs to scale greater academic heights in the United States. Many IMGs who come to the United States as exchange visitors specifically to receive subspecialty training at this country's expense often find that their acquired expertise is inappropriate in their home nations because of a lack of facilities and resources. As a world leader, the United States has a role to help other nations, but some IMGs may not feel a debt to their home countries, and some are "world citizens" whose background and upbringing do not allow them to identify with a particular country of origin (3) . Not only will the use of such IMGs as primary care providers, through necessary legislation, help to alleviate the physician shortage, but it will also give them their due recognition as mainstream health care providers in a land of such ethnic diversity (4).
Srinivas S. Vasireddi, MD Jayadeva Chowdappa, MD
New York, NY 11426-1802 and group D, 6.30). This effect is also stronger than the tendency for women (who are more highly represented in program groups C and D than in groups A and B) to subspecialize at a lower rate.
The groups of programs that will be most vulnerable to reductions under graduate medical education reform, however, depends largely on the specific implementation of that reform and is presently unknown. Approaches may include individual programs to respond to local economic and political pressures, may stem from national professional organizations such as the Accreditation Council for Graduate Medical Education or the various boards, or may take the form of national or state legislative action. Currently, all proactive approaches to graduate medical education reform recognize program "quality" as an importantguide to program reduction. For the reasons outlined in our report, we believe that as a group, the programs with the highest proportions of IMG residents may be the most subject to questions about "quality." The issues are the following: Can these questions be successfully answered? If so, how? If not, what are the implications for the teaching hospitals involved?
Drs. Vasireddi and Chowdappa raise a somewhat different set of issues, and we agree that IMG residents and physicians play important roles in the U.S. health care system. We also agree that there are dangers in generalizing the behavior of groups (2). However, IMGs constitute an important policy group. Not only do they (as a group) show different behavior (for example, higher rates of subspecialization), but they also present different problems in training, and, most significantly, they are easily targeted by federal immigration policy. In the current atmosphere of concern in health care about the generalist-specialist mix in the physician work force, we must resist any temptation to make IMGs the scapegoats.
Adult Immunizations 1994
To the Editor: The editorial about adult immunization (1) did not mention international air travelers. These people are at high risk for influenza, and I think that they should be immunized with the influenza vaccine. Airplanes have poor air circulation (obviously the windows cannot be opened), and if someone has influenza and is coughing or sneezing, many persons will breath in those viral particles.
The influenza vaccine is a safe and inexpensive vaccine. Persons who intend to travel outside the United States should receive the influenza vaccine when they visit their internist for a pretravel consultation. This vaccine will be more valuable than most tropical vaccines, such as those for yellow fever or cholera, especially for the business traveler who rarely gets exposed to any serious illness except influenza. I am not aware of any studies that "prove" the need for the influenza vaccine for airplane travelers, but, from my experience in travel medicine, immunization recommendations should include the influenza vaccine for international travelers.
Ronald J. Bloomfield, MD
Mount Carmel Medical Center Columbus, OH 43222
